Rebooting the Body

Dolan, Kerry A.
December 2006
Forbes Asia;12/11/2006, Vol. 2 Issue 21, p88
The article focuses on the adult stem cells being produced by Cellerant Therapeutics in San Carlos, California. The stem cell promises to revive the diseased bloodstreams of sufferers of sickle-cell anemia, lupus, Crohn's disease and Type 1 diabetes. The company was given $2 million in grants by the U.S. National Institutes of Health to develop a blood-regenerating therapy to treat irradiated victims of a nuclear attack. The company's effort to transplant unaltered human cells allows it to be exempted from clinical trials.


Related Articles

  • Tulane takes shot at cure for ravages of lung disease. Webster, Richard A. // New Orleans CityBusiness (1994 to 2008);8/29/2005, Vol. 26 Issue 8, p7 

    Presents the research grant awarded by the U.S. National Institutes of Health to Tulane Center for Gene Therapy, to study the use of adult stem cells in treating lung disease. Aim of the grant to discover cure for treating lung diseases, such as emphysema, asbestos exposure and cystic fibrosis;...

  • Sickle Cell Disease.  // Sickle Cell Disease Fact Sheet;2010, p1 

    The article presents facts about sickle cell disease (SCD). Studies supported by the U.S. National Institutes of Health (NIH) have helped improve the longevity of patients with sickle cell (SC) anemia and those with a related condition, SC-hemoglobin disease. NIH Clinical Center researchers have...

  • BRIEFS.  // Bio-IT World;Feb2003, Vol. 2 Issue 2, p12 

    Presents news briefs on the biotechnology industry in the U.S. as of February 2003. Construction of the New York Structural Genomics Center by the joint efforts of universities and research hospitals; Development of a program by the Theoretical Biophysics Group at the University of Illinois in...

  • Early Pathologic Findings of Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation: A Proposal from a Case. Nakamoto-Matsubara, Rie; Nishikii, Hidekazu; Yamada, Kenji; Ito, Masafumi; Hasegawa, Yuichi; Kurita, Naoki; Obara, Naoshi; Okoshi, Yasushi; Suzukawa, Kazumi; Yokoyama, Yasuhisa; Sakata-Yanagimoto, Mamiko; Noguchi, Masayuki; Chiba, Shigeru // Case Reports in Hematology;2012, p1 

    Bronchiolitis obliterans (BO) is one of the serious, noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early diagnosis of BO is usually difficult because patients are often asymptomatic at an initial stage of the disease and pathologic...

  • Transcription factor directed differentiation of human embryonic stem cells into the pancreatic endocrine lineage. Qing Le Liang; Xiao Xun Wang; Xiao Fei Yan; Li Jun Yang; Dong Qi Tang; Dong Sheng Li // Cell Research;Aug2008 Supplement, Vol. 18, pS109 

    Human embryonic stem (hES) cells represent a potentially unlimited source of transplantable beta-cells for the treatment of diabetes. It has been reported that hES cells can be directly induced through cytokines or gene manipulations to insulin-producing cells ((IPCs). Here we describe a novel...

  • Dr. Eva Feldman.  // Ability;Aug/Sep2013, p12 

    An interview with neurology professor Eva Feldman at the University of Michigan is presented. When asked about the process of transplanting stem cells, she says that transplanting of stem cells are processed through surgery. She states that creating embryonic stem cell lines are illegal in...

  • Health-related quality of life in pediatric patients after allogeneic SCT: development of the PedsQL Stem Cell Transplant module and results of a pilot study. Lawitschka, A; Güclü, E D; Varni, J W; Putz, M; Wolff, D; Pavletic, S; Greinix, H; Peters, C; Felder-Puig, R // Bone Marrow Transplantation;Aug2014, Vol. 49 Issue 8, p1093 

    With increased survival after pediatric allogeneic hematopoietic SCT health-related quality of life (HRQL) has emerged as an essential health outcome. The impact of transplant and chronic GVHD (cGVHD)-associated morbidity remains a major obstacle. In 2005, the National Institutes of Health (NIH)...

  • Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD. Inamoto, Y; Jagasia, M; Wood, W A; Pidala, J; Palmer, J; Khera, N; Weisdorf, D; Carpenter, P A; Flowers, M E D; Jacobsohn, D; Martin, P J; Lee, S J; Pavletic, S Z // Bone Marrow Transplantation;Apr2014, Vol. 49 Issue 4, p532 

    The 2005 National Institutes of Health (NIH) consensus criteria for chronic GVHD have set standards for reporting. Many questions, however, have arisen regarding their implementation and utilization. To identify perceived areas of controversy, we conducted an international survey on diagnosis...

  • NIH embryo policy draws bilateral fire.  // Medical Device Daily;4/21/2009, Vol. 13 Issue 75, p4 

    The article reports on a draft guideline published by the U.S. National Institutes of Health for dealing with the use of embryos as a source of stem cells. According to the guideline, NIH would restrict embryo use to those created for reproductive purposes but have not been used and scheduled...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics